First National Bank & Trust Co. of Newtown Sells 398 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

First National Bank & Trust Co. of Newtown lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,019 shares of the medical equipment provider’s stock after selling 398 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Zimmer Biomet were worth $213,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Ieq Capital LLC raised its position in Zimmer Biomet by 65.6% in the fourth quarter. Ieq Capital LLC now owns 9,853 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,904 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of Zimmer Biomet by 25.5% in the 4th quarter. Private Advisor Group LLC now owns 13,879 shares of the medical equipment provider’s stock valued at $1,466,000 after purchasing an additional 2,822 shares during the period. Venturi Wealth Management LLC raised its holdings in shares of Zimmer Biomet by 950.3% in the 4th quarter. Venturi Wealth Management LLC now owns 1,859 shares of the medical equipment provider’s stock worth $196,000 after buying an additional 1,682 shares in the last quarter. D.A. Davidson & CO. lifted its position in shares of Zimmer Biomet by 36.4% during the 4th quarter. D.A. Davidson & CO. now owns 11,907 shares of the medical equipment provider’s stock worth $1,258,000 after buying an additional 3,175 shares during the period. Finally, Citizens & Northern Corp boosted its stake in Zimmer Biomet by 5.0% in the 4th quarter. Citizens & Northern Corp now owns 12,811 shares of the medical equipment provider’s stock valued at $1,353,000 after buying an additional 610 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.1 %

ZBH stock opened at $103.31 on Thursday. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The business’s 50 day simple moving average is $105.96 and its 200 day simple moving average is $107.51. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $20.57 billion, a PE ratio of 23.22, a PEG ratio of 1.93 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company earned $2.20 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.93%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

A number of research analysts have issued reports on ZBH shares. Truist Financial reissued a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.